CTCFL and cancer: For this purpose, we developed a large set of anti-CTCF and anti-BORIS mouse monoclonal antibodies, thoroughly validated by immunoblotting, electrophoretic mobility shift assay (EMSA), and ChIP-seq for both BORIS-positive cancer cells and BORIS-negative normal human dermal fibroblasts (NHDFs) (Fig. 1c–h; Fig. S1b-d in Additional file 1).